Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.
de Petris, L
Blackhall, Fiona H
AffiliationMedical and Health Sciences, Linkoping University
MetadataShow full item record
AbstractChemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.
CitationUsing whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities. 2015: Clin Cancer Res
JournalClinical Cancer Research
- Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
- Authors: Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA
- Issue date: 1999 Mar 15
- Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
- Authors: Thomas P, Robinet G, Ferri-Dessens RM, Léna H, Gouva S, Vernejoux JM, Kleisbauer JP
- Issue date: 2002 May
- Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
- Authors: Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL
- Issue date: 2001 May
- A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
- Authors: Ng EW, Sandler AB, Robinson L, Einhorn LH
- Issue date: 1999 Dec
- A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
- Authors: Carmichael J, Allerheiligen S, Walling J
- Issue date: 1996 Oct